Advertisement
Advertisement
U.S. markets close in 12 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Voyager Therapeutics, Inc. (VYGR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.25-0.20 (-3.10%)
As of 03:48PM EST. Market open.
Advertisement

Voyager Therapeutics, Inc.

75 Sidney Street
Cambridge, MA 02139
United States
857 259 5340
https://www.voyagertherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees101

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert W. HessleinSr. VP & Gen. Counsel576.62kN/A1953
Mr. G. Andre TurenneAdvisor600.3kN/A1974
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.Pres, CEO & DirectorN/AN/A1958
Dr. Krystof Bankiewicz M.D., Ph.D.FounderN/AN/AN/A
Dr. Guangping Gao Ph.D.FounderN/AN/AN/A
Dr. Mark A. Kay M.D., Ph.D.FounderN/AN/A1958
Dr. Phillip D. ZamoreFounderN/AN/AN/A
Mr. Peter P. Pfreundschuh CPAChief Financial OfficerN/AN/A1969
Ms. Robin SwartzChief Operating OfficerN/AN/A1971
Mr. Todd Carter Ph.D.Chief Science OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Voyager Therapeutics, Inc.’s ISS Governance QualityScore as of December 1, 2022 is 7. The pillar scores are Audit: 3; Board: 8; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement